Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper 2

84O - Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816

Date

30 Mar 2023

Session

Proffered Paper 2

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Nicolas Girard

Citation

Journal of Thoracic Oncology (2023) 18 (4S): S89-S100.
<article-id>elcc_Ch02

Authors

N. Girard1, J. Spicer2, M. Provencio3, S. Lu4, C. Wang5, M. Awad6, T. Mitsudomi7, E. Felip8, S.J. Swanson6, G. Saylors9, K. Chen10, F. TANAKA11, M.(. Tran12, N. Hu13, J. Cai12, J. Bushong12, J. Neely12, D. Balli12, S.R. Broderick14

Author affiliations

  • 1 Institut Curie, Paris/FR
  • 2 McGill University Health Centre, Montreal/CA
  • 3 Hospital Universitario Puerta de Hierro, Madrid/ES
  • 4 Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai/CN
  • 5 Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin/CN
  • 6 Dana-Farber Cancer Institute, Boston/US
  • 7 Kindai University Faculty of Medicine, Osaka-Sayama/JP
  • 8 Vall d'Hebron Institute of Oncology, Barcelona/ES
  • 9 Charleston Oncology, Charleston/US
  • 10 Peking University School of Oncology, Beijing Cancer Hospital, Beijing/CN
  • 11 University of Occupational and Environmental Health, Kitakyushu/JP
  • 12 Bristol Myers Squibb, Princeton/US
  • 13 Bristol Myers Squibb, 8540 - Princeton/US
  • 14 Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore/US

Resources

This content is available to ESMO members and event participants.

Abstract 84O

Background

The phase III CheckMate 816 study demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and pathologic complete response (pCR) with neoadjuvant N + C vs C in patients (pts) with resectable NSCLC. Here, we report 3-y efficacy, safety, and exploratory biomarker analyses from CheckMate 816.

Methods

Adults with stage IB (tumors ≥4 cm)–IIIA (per AJCC 7th ed) resectable NSCLC, ECOG PS ≤ 1, and no known EGFR/ALK alterations were randomized to N 360 mg + C Q3W or C alone Q3W for 3 cycles followed by surgery. Primary endpoints were EFS and pCR, both per blinded independent review. Exploratory analyses included EFS by surgical approach and extent/completeness of resection, and EFS and pCR by a 4-gene (CD8A, CD274, STAT-1, LAG-3) inflammatory signature score derived from RNA sequencing of baseline (BL) tumor samples.

Results

At a median follow-up of 41.4 mo (database lock, Oct 14, 2022), continued EFS benefit was observed with N + C vs C (HR, 0.68; 95% CI, 0.49–0.93); 3-y EFS rates were 57% and 43%, respectively. N + C improved EFS vs C in pts who had surgery, regardless of surgical approach or extent of resection, and in pts with R0 resection (table). Recurrence occurred in 28% and 42% of pts who had surgery in the N + C (n = 149) and C arms (n = 135), respectively. In the N + C arm, BL 4-gene inflammatory signature scores were numerically higher in pts with pCR vs pts without, and EFS was improved in pts with high vs low scores (data to be presented). Grade 3–4 treatment-related and surgery-related adverse events occurred in 36% and 11% of pts in the N + C arm, respectively, vs 38% and 15% in the C arm.

Table: 84O
N + CCN + C vs C
nEFSnEFSHR(95% CI)
Median(95% CI), mo3-y rate, %Median(95% CI), mo3-y rate, %
All randomized pts179NR(31.6–NR)5717921.1(14.8–42.1)430.68(0.49–0.93)
Surgical approach
Minimally invasive44NR(30.8–NR)6729NR(9.5–NR)530.61(0.28–1.29)
Thoracotomy or conversion105NR(40.4–NR)6110642.1(18.2–NR)510.74(0.48–1.13)
Extent of resection
Lobectomy115NR(44.4–NR)648234.3(16.6–NR)490.62(0.40–0.96)
Pneumonectomy25NR(19.4–NR)673421.1(13.9–NR)48NCa
Completeness of resection
R0124NR(44.4–NR)6410542.1(19.6–NR)510.65(0.43–0.98)
R1/R221NR(12.6–NR)5325NR(10.8–NR)57NCa
a

Too few events (< 10 per arm) to calculate HR.

NC, not calculated; NR, not reached.

Conclusions

Neoadjuvant N + C continues to provide long-term clinical benefit vs C in pts with resectable NSCLC, regardless of surgical approach or extent of resection. Exploratory analyses in pts treated with N + C suggested that high BL tumor inflammation may be associated with improved EFS and pCR.

Clinical trial identification

NCT02998528.

Editorial acknowledgement

Medical writing and editorial support for the development of this abstract, under the direction of the authors, was provided by Adel Chowdhury, PharmD, Samantha Dwyer, PhD, and Michele Salernitano of Ashfield MedComms, an Inizio company, and funded by Bristol Myers Squibb.

Legal entity responsible for the study

Bristol Myers Squibb.

Funding

Bristol Myers Squibb.

Disclosure

P.M. Forde: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, F-Star, G1 Therapeutics, Genentech, Iteos, Janssen, Merck, Novartis, Sanofi, Surface; Financial Interests, Institutional, Research Grant: AstraZeneca, BioNTech, Bristol Myers Squibb, Corvus, Kyowa, Novartis, Regeneron; Financial Interests, Personal, Other, Trial steering committee member: AstraZeneca, BioNTech, Bristol Myers Squibb, Corvus; Non-Financial Interests, Personal, Member of the Board of Directors: Mesothelioma Applied Research Foundation; Non-Financial Interests, Personal, Advisory Role, Scientific advisory board member: LUNGevity Foundation.

J. Spicer: Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb, CLS Therapeutics, Merck, Protalix Biotherapeutics, Roche; Financial Interests, Personal, Other, Consulting fees: Amgen, AstraZeneca, Bristol Myers Squibb, Merck, Novartis, Protalix Biotherapeutics, Regeneron, Roche, Xenetic Biosciences; Financial Interests, Personal, Speaker's Bureau: AstraZeneca, Bristol Myers Squibb, PeerView; Non-Financial Interests, Personal, Other, Data safety monitoring board member: Deutsche Forschungsgemeinschaft; Non-Financial Interests, Personal, Leadership Role, Industry chair: Canadian Association of Thoracic Surgeons.

N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer Ingelheim, Novartis, Sanofi, AbbVie, Amgen, Eli Lilly, Grunenthal, Takeda, Owkin; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS; Non-Financial Interests, Personal, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Personal, Other, Family member is an employee: AstraZeneca.

M. Provencio: Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb, Janssen, Pfizer, Roche, Takeda; Financial Interests, Personal, Speaker's Bureau: AstraZeneca, Bristol Myers Squibb, MSD, Pfizer, Roche, Takeda.

S. Lu: Financial Interests, Personal, Advisory Role: AstraZeneca, Boehringer Ingelheim, GenomiCare, Hutchison MediPharma, Roche, Simcere, ZaiLab; Financial Interests, Personal, Speaker's Bureau: AstraZeneca, Hanosh, Roche.

M. Awad: Financial Interests, Personal, Other, Consulting fees: ArcherDX, Ariad, AstraZeneca, Blueprint Medicine, Bristol Myers Squibb, EMD Serono, Genentech, Maverick, Merck, Mirati, Nektar, NextCure, Novartis, Syndax; Financial Interests, Institutional, Research Grant: AstraZeneca, Bristol Myers Squibb, Genentech, Eli Lilly.

T. Mitsudomi: Financial Interests, Institutional, Research Grant: Boehringer Ingelheim, BridgeBio Pharma; Financial Interests, Personal, Other, Consulting fees: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, MSD, Novartis, Ono, Pfizer; Financial Interests, Personal, Speaker's Bureau: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, Guardant, Invitae, Merck, MSD, Novartis, Ono, Pfizer, Taiho; Financial Interests, Personal, Advisory Board: AstraZeneca; Non-Financial Interests, Personal, Leadership Role, Former president: IASLC.

E. Felip: Financial Interests, Institutional, Research Grant: Fundación Merck Salud, Merck KGAa; Financial Interests, Personal, Other, Consulting fees: Amgen, AstraZeneca, Bayer, BerGenBio, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, GlaxoSmithKline, Janssen, Merck, MSD, Novartis, Peptomyc, Pfizer, Sanofi, Takeda; Financial Interests, Personal, Speaker's Bureau: Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Janssen, Medical Trends, Medscape, Merck, MSD, PeerVoice, Pfizer, Sanofi, Takeda, touchONCOLOGY; Non-Financial Interests, Personal, Member of the Board of Directors: Grífols.

S.J. Swanson: Financial Interests, Personal, Speaker's Bureau: Ethicon.

F. Tanaka: Financial Interests, Institutional, Research Grant: Boehringer Ingelheim, Chugai, Eli Lilly, Ono, Taiho; Financial Interests, Personal, Other, Consulting fees: AstraZeneca, Chugai, Ono; Financial Interests, Personal, Speaker's Bureau: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Covidien, Eli Lilly, Intuitive, Johnson & Johnson, Kyowa Kirin, MSD, Olympus, Ono, Pfizer, Stryker, Taiho, Takeda.

P. Tran: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb.

N. Hu: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb.

J. Cai: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb; Financial Interests, Personal, Other, Travel support for attending meetings and travel: Bristol Myers Squibb.

J. Bushong: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb.

J. Neely: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb.

D. Balli: Financial Interests, Personal, Other, patents planned, issued, or pending: Bristol Myers Squibb; Financial Interests, Personal, Stocks/Shares: Bristol Myers Squibb.

S.R. Broderick: Financial Interests, Personal, Advisory Board: AstraZeneca.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.